BMS-P5

• Description:

  BMS-P5 is a selective and orally active peptidylarginine deiminase 4 (PAD4) inhibitor with an IC50 of 98 nM. BMS-P5 shows selective for PAD4 over PAD1, PAD2, and PAD3. BMS-P5 blocks multiple myeloma (MM) -induced neutrophil extracellular trap (NET) formation and delays progression of MM in a syngeneic mouse model[1].

• UNSPSC:

  12352005

• Target:

  Protein Arginine Deiminase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bms-p5.html

• Purity:

  99.23

• Solubility:

  DMSO : 35 mg/mL (ultrasonic)

• Smiles:

  O=C(N1[C@@H](C)CC[C@@H](N)C1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC6CC6)N3C)=C2.[H]Cl

• Molecular Formula:

  C27H33ClN6O2

• Molecular Weight:

  509.04

• References & Citations:

  [1]Marina Li, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19 (7) :1530-1538.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1549811-36-0